In 2018, Kuros Biosciences recorded the first sales of its MagnetOs bone graft substitute in the U.S. and Europe and raised capital to fund a phase 2 clinical trial of its spinal fusion product.
Biologics
Sharonville, Ohio-based Beacon Orthopaedics & Sports Medicine is offering orthobiologic and regenerative medicine treatment options for patients with neck and spine pain, Fox19.com reports.
Royal Biologics is an orthobiologics company focused on regenerative cellular technology.
The FDA plans to crackdown on unsubstantiated and poor quality stem cell therapies in 2019, Law 360 reports.
Axolotl Biologix released the Axolotl Shot, a syringe preloaded with ambient temperature regenerative fluid that physicians can apply to patients during same-day, outpatient visits.
Advertisement
Dakota Dunes, S.D.-based Center for Neurosciences, Orthopaedics & Spine physicians have used platelet rich plasma injections to treat more than 100 joint pain patients, according to KTIV News.
The Japanese Pharmaceuticals and Medical Devices Agency granted DiscGenics approval for a clinical trial notification application for its IDCT, an allogeneic, injectable disc cell therapy for degenerative disc disease.
Kuros Biosciences received FDA 510(k) clearance to extend its MagnetOs Putty indications to use as a standalone bone graft in the extremities and pelvis.
Kuros Biosciences' MagnetOs is a suitable alternative to autograft for spinal fusion when used as a standalone graft, according to an animal study in JOR Spine.
Carmell Therapeutics is a biotechnology company focused on plasma-based bioactive materials.